Of note, earlier studies demonstrating increased interferon-gamma production by NK cells following treatment of mCMV-infected mice with a VIP-R antagonist23 suggests that NK cells may also contribute to the anti-cancer immune responses seen in tumor-bearing mice treated with a VIP-R antagonist. This evidence concerns the gene IFNG and neoplasm.